					_					
AMENDMENT TRANSMITTAL LETTER (Small Entity) Applicant(s): Ron et al.						Docket No. 13257-00040 (UMD-0096)				
Application No. 09/830,176	Filing Date April 23, 2001	Examiner Joseph T. Woitacl	h	Customer N 46046	0.	Group Art Unit	Confirmation No. 2969			
Wenton A MYELOID PRECURSOR CELL USEFUL FOR GENE THERAPY AND FOR MODULATION OF IMMUNE RESPONSES MAR 0 2 7005										
COMMISSIONER FOR PATENTS:										
Transmitted herewith is an amendment in the above-identified application.										
Applicant claims small entity status. See 37 CFR 1.27										
The fee has been calculated and is transmitted as shown below.										
	·	CLAIMS AS AM	ENDED							
	CLAIMS REMAINING	HIGHEST #	NUMBI	ER EXTRA	RATE		ADDITIONAL			
	AFTER AMENDMENT	PREV. PAID FOR	CLAIMS	PRESENT			FEE			
TOTAL CLAIMS	. 5 -	20 =			X	\$25.00	\$0.00			
INDEP. CLAIMS	2 -	6 =		0	X	\$100.00	\$0.00			
Multiple Dependent Claims (check if applicable)										
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT \$0							\$0.00			
No additional fee is required for amendment. ☐ Please charge Deposit Account No. in the amount of ☐ A check in the amount of to cover the filing fee is enclosed. ☐ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-1619 ☐ Any additional filing fees required under 37 C.F.R. 1.16. ☐ Any patent application processing fees under 37 CFR 1.17. ☐ Payment by credit card. Form PTO-2038 is attached. ☐ WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. ☐ Dated: March 2, 2005 ☐ Leating March 2										
Marlton, NJ 08053 Tel: 856-810-1515 Fax: 856-810-1454 Signature of Person Mailing Correspondence							espondence			
cc:				Typed or Printed Name of Person Mailing Correspondence						

		<u> </u>					
CERTIFICATE O Applicant(s): Ron et a	Docket No. 13257-00040 (UMD-0096)						
Application No. 09/830,176	Filing Date April 23, 2001	Examiner Joseph T. Woitach	Customer No. 46046	Group Art Unit			
MAR 0 2 2005	OID PRECURSOR CELL ATION OF IMMUNE RES	USEFUL FOR GENE THERAPY AND PONSES	D FOR	-,			
	the following corresponde	under 37 C.F.R. 1.111					
	0	dentify type of correspondence)					
		stal Service "Express Mail Post Office missioner for Patents, P.O. Box 1450					
· —	March 2, 2005 (Date)						
		Jane Massey Licata (Typed or Printed Name of Person Mailing Correspondence)					
		(Signature of Person Mai	lling Correspondence)				
		EV58391 ("Express Mail" Mail					

Note: Each paper must have its own certificate of mailing.



3-3-05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:

13257-00040 (UMD-0096)

Inventors:

Ron et al.

Serial No.:

09/830,176

Filing Date:

April 23, 2001

Examiner:

Woitach, Joseph T.

Customer No.:

46046

Group Art Unit:

1632

Confirmation No.:

2969

Title:

A Myeloid Precursor Cell Useful for Gene

Therapy and for Modulation of Immune

Responses

"Express Mail" Label No. EV583917180US Date of Deposit March 2, 2005

t hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Mail Stop Non-Fee Amendment,

P. O. Box 1450, Alexandria, VA 22313-1450.

Janantust Typed Name: Jane Massey Licata, Reg. No. 32,257

Commissioner for Patents Mail Stop Non-Fee Amendment P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Reply Under 37 C.F.R. § 1.111

This is a reply to the Office action mailed December 15, 2004 setting a three (3) month statutory period for reply. Please enter the following remarks and amendments into the

Amendments to the Specification begin on page 3 of this paper.

Attorney Docket No.: 13257-00040 (UMD-0096)

Inventors: Ron et al.
Serial No.: 09/830,176
Filing Date: April 23, 2001

Page 2

Amendments to the Claims are reflected in the listing of claims which begin on page 5 of this paper.

Remarks/Arguments begin on page 7 of this paper.